Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate

ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bind the active site zinc, however, in recent years,...

Descripción completa

Detalles Bibliográficos
Autores principales: Madoux, Franck, Dreymuller, Daniela, Pettiloud, Jean-Phillipe, Santos, Radleigh, Becker-Pauly, Christoph, Ludwig, Andreas, Fields, Gregg B., Bannister, Thomas, Spicer, Timothy P., Cudic, Mare, Scampavia, Louis D., Minond, Dmitriy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431342/
https://www.ncbi.nlm.nih.gov/pubmed/28442704
http://dx.doi.org/10.1038/s41598-016-0013-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431342/
https://www.ncbi.nlm.nih.gov/pubmed/28442704
http://dx.doi.org/10.1038/s41598-016-0013-4

Ejemplares similares